IRIS UniCatt

Andreotti, Felicita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.121
AS - Asia 4.467
EU - Europa 3.226
SA - Sud America 899
AF - Africa 127
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 13.865
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.976
SG - Singapore 2.145
CN - Cina 1.081
BR - Brasile 736
DE - Germania 691
SE - Svezia 683
IT - Italia 456
VN - Vietnam 359
FR - Francia 330
UA - Ucraina 222
IE - Irlanda 216
GB - Regno Unito 173
ID - Indonesia 146
RU - Federazione Russa 121
JP - Giappone 113
IN - India 110
HK - Hong Kong 101
BD - Bangladesh 94
FI - Finlandia 91
CA - Canada 65
IQ - Iraq 58
TR - Turchia 55
AR - Argentina 53
NL - Olanda 40
ZA - Sudafrica 38
PL - Polonia 37
MX - Messico 35
KR - Corea 34
AT - Austria 28
EC - Ecuador 27
CO - Colombia 25
SA - Arabia Saudita 25
BE - Belgio 22
PK - Pakistan 22
CL - Cile 18
KE - Kenya 17
CZ - Repubblica Ceca 15
ES - Italia 15
AE - Emirati Arabi Uniti 14
AU - Australia 13
VE - Venezuela 13
ET - Etiopia 12
IR - Iran 12
LT - Lituania 12
MA - Marocco 12
PY - Paraguay 12
CH - Svizzera 11
EG - Egitto 10
RO - Romania 10
JO - Giordania 9
AZ - Azerbaigian 8
EU - Europa 8
IL - Israele 8
PH - Filippine 8
JM - Giamaica 7
PE - Perù 7
TT - Trinidad e Tobago 7
CR - Costa Rica 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
NP - Nepal 6
UZ - Uzbekistan 6
BG - Bulgaria 5
CI - Costa d'Avorio 5
HN - Honduras 5
HU - Ungheria 5
KZ - Kazakistan 5
QA - Qatar 5
TH - Thailandia 5
TN - Tunisia 5
UY - Uruguay 5
BB - Barbados 4
BY - Bielorussia 4
CY - Cipro 4
GR - Grecia 4
KG - Kirghizistan 4
KW - Kuwait 4
LU - Lussemburgo 4
MY - Malesia 4
NG - Nigeria 4
OM - Oman 4
PT - Portogallo 4
TW - Taiwan 4
AL - Albania 3
BO - Bolivia 3
DK - Danimarca 3
GE - Georgia 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BT - Bhutan 2
CG - Congo 2
EE - Estonia 2
GT - Guatemala 2
IS - Islanda 2
LK - Sri Lanka 2
ML - Mali 2
Totale 13.831
Salva come PNG Salva come JPEG
Città #
Singapore 1.090
Ashburn 630
Chandler 612
San Jose 549
Beijing 262
Dublin 209
New York 165
San Mateo 162
Jakarta 133
Ho Chi Minh City 127
Hangzhou 118
Lauterbourg 114
Wilmington 113
Jacksonville 109
Nanjing 103
Tokyo 103
Los Angeles 99
Hefei 95
Hong Kong 95
Boston 94
Cattolica 93
Munich 85
Milan 83
Princeton 83
Hanoi 82
St Louis 76
Moscow 75
Frankfurt am Main 74
São Paulo 64
Rome 63
Ann Arbor 56
Dallas 53
Menlo Park 52
Lancaster 50
Bremen 49
Chicago 48
Houston 41
Santa Clara 39
Redwood City 38
Boardman 37
Woodbridge 37
Seattle 36
Dearborn 35
Nanchang 35
Fairfield 34
Marseille 34
Buffalo 30
Lawrence 30
Nuremberg 29
Kent 28
Izmir 27
Helsinki 25
Seoul 25
Rio de Janeiro 23
Warsaw 23
Baghdad 22
Council Bluffs 22
Atlanta 20
Brussels 20
Da Nang 19
Mountain View 19
Paris 19
The Dalles 19
London 18
Montreal 18
Nürnberg 18
Toronto 18
Norwalk 17
Pune 17
Redmond 17
Shanghai 16
Vienna 16
Memphis 15
Shenyang 15
Zhengzhou 15
Haiphong 14
Johannesburg 14
Nairobi 14
San Francisco 14
Amsterdam 13
Brasília 13
Curitiba 13
Dhaka 13
Düsseldorf 13
Florence 13
Phoenix 13
Turku 13
Washington 13
Augusta 12
Hebei 12
Kunming 12
Stockholm 12
Tianjin 12
Belo Horizonte 11
Brooklyn 11
Cape Town 11
Jiaxing 11
Orem 11
Padova 11
Biên Hòa 10
Totale 7.343
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 216
Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women 215
Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients 191
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 190
Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus 181
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function 171
Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials 167
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 156
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials 149
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 146
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS) 142
Bedside monitoring of antiplatelet therapy for coronary stenting 142
IGF-1 and microvascular complications of diabetes: alternative interpretation of recently published data 139
Body fat and cardiovascular risk: understanding the obesity paradox 139
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 139
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction 137
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 137
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 136
Evolocumab and clinical outcomes in patients with cardiovascular disease 135
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 132
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 131
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 131
A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. 130
Testosterone, tissue factor inhibition and vascular aging 128
2024 ESC Guidelines for the management of chronic coronary syndromes 126
The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? 126
Mechanisms, pathophysiology, and management of obesity 125
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology 124
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor 124
Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: A systematic review and meta-analysis 124
Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies 123
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials 122
Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI 122
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome 120
Anemia contributes to cardiovascular disease through reductions in nitric oxide 119
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 119
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology 118
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 117
Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass 115
EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis 114
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 114
Sex differences in mechanisms, presentation and management of ischaemic heart disease 112
Last word on viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide 112
Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients 110
Polycythemia, vascular function, and hemoglobin-nitric oxide reactions 109
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis 109
Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery 109
Hemoglobin levels, nitric oxide bioavailability and cardiovascular outcomes 108
Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization 107
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 106
Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR 101
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials 101
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: A prospective study 100
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 100
Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation 99
The unstable plaque: a broken balance 99
[Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation] 99
Mechanisms, Pathophysiology, and Management of Obesity 98
Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes 98
Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry 97
Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis 96
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis 96
Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials 95
Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial) 95
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension 95
Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies 94
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis 94
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 94
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: A review 94
Bedside monitoring of antiplatelet therapy for coronary stenting 93
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 92
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 92
Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: Not a matter of faith 92
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention 91
How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review 91
Women and coronary disease 91
Fibrinogen as a marker of inflammation: a clinical view 91
The G20210A prothrombin mutation and the Physicians' Health Study 91
Inflammatory and fibrinolytic activation after coronary artery bypass graft 90
Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: A systematic review and meta-analysis 90
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 90
G20210A Prothrombin gene polymorphism and coronary ischaemic syndromes: A phenotype-specific meta-analysis of 12 034 subjects 89
PCI for Ischemic Left Ventricular Dysfunction 89
Leading avoidable cause of premature deaths worldwide: case for obesity 89
G20210A prothrombin gene polymorphism and extent of coronary disease 89
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: A jump with a weak parachute? 88
G20210A protrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 87
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper 87
Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism 87
Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects 87
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: The 'OPTIMIZE-IT' pilot randomized study 86
Family history in first degree relatives of patients with premature cardiovascular disease 85
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial 85
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 84
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management 82
Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives 82
Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine 82
Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes 82
Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention? 82
Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention? 82
Totale 11.277
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022929 73 64 8 66 54 23 20 167 40 50 193 171
2022/20231.958 307 255 149 250 145 232 78 154 248 41 67 32
2023/20241.172 45 296 23 155 29 139 59 105 25 42 134 120
2024/20252.144 44 53 149 78 163 54 50 129 399 175 450 400
2025/20265.657 949 160 350 645 927 265 903 281 366 455 178 178
2026/202757 57 0 0 0 0 0 0 0 0 0 0 0
Totale 14.061